Pfizer now expects COVID vaccine sales to reach $33.5B this year, a whopping $7.5B bump from its estimate 3 months agonews2021-07-28T11:56:46+00:00July 28th, 2021|Fierce Pharma|
Google’s cookie ban delay prompts sighs of relief, but pharma advertisers shouldn’t get complacent: digital media execnews2021-07-28T03:43:45+00:00July 28th, 2021|Fierce Pharma|
Moderna and Novavax grapple with COVID-19 vaccine supply hiccups overseas: reportsnews2021-07-27T19:43:38+00:00July 27th, 2021|Fierce Pharma|
‘I don’t like it:’ Biogen’s latest Alzheimer’s ad rouses fresh Aduhelm concerns—and some defensenews2021-07-27T17:41:21+00:00July 27th, 2021|Fierce Pharma|
Lawmakers press FDA for answers about its plans to restart foreign inspectionsnews2021-07-27T16:11:21+00:00July 27th, 2021|Fierce Pharma|
Pharma giants, led by Pfizer and J&J, play COVID card to fight global tax deal: WSJnews2021-07-27T15:22:52+00:00July 27th, 2021|Fierce Pharma|
GlaxoSmithKline debuts DTC campaign for lupus med Benlysta as it looks to cement category leadnews2021-07-27T15:10:38+00:00July 27th, 2021|Fierce Pharma|
Purdue points to creditor support for bankruptcy plan to escape opioid litigation but will Congress follownews2021-07-27T14:06:45+00:00July 27th, 2021|Fierce Pharma|
Pfizer, Mylan escape another EpiPen lawsuit after judge scraps pharmacy chain’s antitrust complaintsnews2021-07-27T13:42:50+00:00July 27th, 2021|Fierce Pharma|
Merck’s Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA’s prior reluctancenews2021-07-27T13:33:48+00:00July 27th, 2021|Fierce Pharma|
